



## Supplementary Materials: Novel Sustained-Release Drug Delivery System for Dry Eye Therapy by Rebamipide Nanoparticles


Noriaki Nagai, Miyu Ishii, Ryotaro Seiriki, Fumihiko Ogata, Hiroko Otake, Yosuke Nakazawa, Norio Okamoto, Kazutaka Kanai, and Naohito Kawasaki




**Figure S1.** Particle size distribution of rebamipide solid in REB-NPs on the day of (A) and 1 month after (B) preparation. The data were obtained by the laser diffraction measurement.



**Figure S2.**  $AUC_{\text{release}}$  for REB-MPs and REB-NPs through the 25 nm (A) and 450 nm (B) pore membranes.  $n = 5-6$ . \* $P < 0.05$ , vs. REB-MPs.



**Figure S3.** Drug release from REB formulations containing dissolved rebamipide through 450 nm pore membranes. The *N,N*-dimethylformamide was used to dissolve the rebamipide.  $n = 4$ .



**Figure S4.** Lacrimal fluid volume (A), mucin levels (B) and TBUT (C) in normal rabbits single applied with REB formulations. The REB formulations were applied for 6 h. \* $P < 0.05$ , vs. None for each group. # $P < 0.05$ , vs. Vehicle for each group.